​

Carisma Therapeutics Stock (NASDAQ:CARM)

ForecastRevenueFinancialsChart
Carisma Therapeutics by TradingView

Previous Close

$0.42

52W Range

$0.38 - $3.16

50D Avg

$0.85

200D Avg

$1.25

Market Cap

$16.20M

Avg Vol (3M)

$213.06K

Beta

-

Div Yield

-

CARM Company Profile

Carisma Therapeutics, Inc., a biopharmaceutical company, develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors. Its solutions are used to play a crucial role in the innate and adaptive immune response, and technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human diseases. Carisma Therapeutics, Inc. has a strategic collaboration agreement with Moderna Inc. Carisma Therapeutics, Inc. was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was incorporated in 2016 and is based in Philadelphia, Pennsylvania.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

107

IPO Date

Feb 06, 2014

Website

CARM Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/ServiceDec 20
License Revenue$11.24M

Fiscal year ends in Dec 23 | Currency in USD

CARM Financial Summary

Dec 23Dec 22Dec 21
Revenue$14.92M$40.00M$26.54M
Operating Income$-86.88M$-38.38M$-40.79M
Net Income$-86.88M$-19.88M$-40.77M
EBITDA$-86.88M$-38.37M$-40.11M
Basic EPS$-259.15$-1.98$-4.47
Diluted EPS$-259.15$-1.98$-4.47

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison

TickerCompany
ZVSAZyVersa Therapeutics, Inc.
CNSPCNS Pharmaceuticals, Inc.
IMMXImmix Biopharma, Inc.
CYTOAltamira Therapeutics Ltd.
ZURAZura Bio Limited
HEPAHepion Pharmaceuticals, Inc.
ENVBEnveric Biosciences, Inc.
PALIPalisade Bio, Inc.